首页 | 本学科首页   官方微博 | 高级检索  
     

食管癌多药耐药机制的研究进展
引用本文:张宏鑫,张颖. 食管癌多药耐药机制的研究进展[J]. 现代药物与临床, 2015, 30(6): 742-746
作者姓名:张宏鑫  张颖
作者单位:长治市人民医院 心胸外科, 山西 长治 046000;长治市人民医院 病理科, 山西 长治 046000
摘    要:化疗是食管癌治疗的主要方法之一,而多药耐药(MDR)现象是目前食管癌化疗过程中遇到的最大障碍。肿瘤MDR是指肿瘤患者经过某种化疗药物长期治疗后,除了对该化疗药物产生耐药性,对其他多种结构和功能不同的抗肿瘤药物亦产生耐药。肿瘤MDR是一个多阶段、多因素参与的复杂过程,包括药物转运蛋白的外排作用、靶酶的变化以及其他参与因素的改变等,主要对食管癌多药耐药机制及其逆转剂的研究进展进行综述。

关 键 词:食管癌  多药耐药  机制  逆转剂
收稿时间:2015-05-11

Research progress on multidrug resistance of esophageal carcinoma
ZHANG Hong-xin and ZHANG Ying. Research progress on multidrug resistance of esophageal carcinoma[J]. Drugs & Clinic, 2015, 30(6): 742-746
Authors:ZHANG Hong-xin and ZHANG Ying
Affiliation:Department of Cardiothoracic Surgery, People's Hospital of Changzhi City, Changzhi 046000, China;Department of Pathology, People's Hospital of Changzhi City, Changzhi 046000, China
Abstract:Chemotherapy is one of the main methods in treatment of esophageal carcinoma. However, multidrug resistance (MDR) is the greatest barrier during the chemotherapeutic process. MDR means that after treatment for a long period with some chemotherapeutic agents, patients resistant not only to this chemotherapeutic drug, but also to other structurally and functionally drugs. MDR is a complicated procedure involving multiple stages and multiple factors, including exocytosis of drug transporters, changes of target enzyme, and other involved factors. MDR mechanism of esophageal carcinoma and reversal agents are summarized in this brief review.
Keywords:esophageal carcinoma  multidrug resistance  mechanism  reversal agents
本文献已被 CNKI 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号